Breast Cancer
Conditions
Keywords
educational material, PASS
Brief summary
This was a multinational, non-interventional, cross-sectional survey conducted among HCPs based in the EU/EEA who prescribe Piqray. The survey assessed the knowledge of HCPs prescribing Piqray in relation to the management of hyperglycemia in patients treated with Piqray.
Interventions
OTHERPiqray Prescriber's/HCP guide for hyperglycemia
oncologists/healthcare professionals (HCPs) prescribing Piqray in the EU/EEA were provided with the Piqray Prescriber's/HCP Guide for hyperglycemia (educational material). The educational material aimed to provide oncologists/HCPs prescribing Piqray with additional measures/guidance prior to, and during treatment with Piqray for the identification and management of hyperglycemia.
Sponsors
Novartis Pharmaceuticals
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
* Had prescribed Piqray to at least 1 locally advanced or MBC patient within 6 months prior to completing the survey. * Provided permission to share their anonymized responses in aggregate with EMA or NCAs, if requested.
Exclusion criteria
HCPs who are direct employees of Novartis, the EMA (or any other regulatory bodies), or ICON.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| assess HCPs' knowledge and understanding of the key information included in the Piqray Prescriber's/HCP Guide for hyperglycemia | Throughout study completion, an average of 1 year | The primary endpoint was a composite endpoint based on the percentages of HCPs with correct responses to all questions included in the composite regarding the below information: * Risk of hyperglycemia and its potential risk factors * Signs and symptoms of hyperglycemia * Recommendations for monitoring for hyperglycemia prior to, and during, treatment with Piqray * Recommendations for managing hyperglycemia during treatment with Piqray. Specifically, the primary endpoint was a weighted composite knowledge score aggregated across the following survey questions: 4A, 5A-C, 6, 8A-C, 10, and 12-15. It was calculated as the number of all correctly answered questions divided by the number of all answered questions (i.e. questions that were answered either correct and not correct - unanswered questions are excluded). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Assess HCPs' reported levels of receipt, and reading, of the Piqray Prescriber's/HCP Guide for hyperglycemia | Throughout study completion, an average of 1 year | Assessed as the percentages of HCPs who report receipt and reading of the same (survey questions 1, 2). |
| Assess HCPs' knowledge levels for each survey question regarding knowledge of, and management of, hyperglycemia | Throughout study completion, an average of 1 year | Assessed as the percentages of HCPs with correct responses to each question (individual responses to survey questions 4-15). |
| Assess the primary source from which HCPs learned about the messages included in the Piqray Prescriber's/HCP Guide for hyperglycemia | Throughout study completion, an average of 1 year | Assessed as the percentages of HCPs who report using each of the possible sources as the primary source they used (survey question 3). |
Countries
Switzerland
Outcome results
None listed